The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 25, 2025

Filed:

Oct. 31, 2018
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Sarah Y. Lee, Mercer Island, WA (US);

Pascal Beauchesne, Seattle, WA (US);

Mark L. Bonyhadi, Sammamish, WA (US);

Ryan L. Crisman, Seattle, WA (US);

Ryan P. Larson, Seattle, WA (US);

Mary Mallaney, Seattle, WA (US);

Christopher Glen Ramsborg, Seattle, WA (US);

Clinton Weber, Seattle, WA (US);

John Matthew Wesner, Seattle, WA (US);

Nathan Yee, Seattle, CA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 2239/48 (2023.05); C12N 2501/2302 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/999 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the incubation and/or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.


Find Patent Forward Citations

Loading…